Cargando…

Emerging therapeutic agents for lung cancer

Lung cancer continues to be the most common cause of cancer-related mortality worldwide. Recent advances in molecular diagnostics and immunotherapeutics have propelled the rapid development of novel treatment agents across all cancer subtypes, including lung cancer. Additionally, more pharmaceutical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dholaria, Bhagirathbhai, Hammond, William, Shreders, Amanda, Lou, Yanyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148871/ https://www.ncbi.nlm.nih.gov/pubmed/27938382 http://dx.doi.org/10.1186/s13045-016-0365-z

Ejemplares similares

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Next generation of immune checkpoint therapy in cancer: new developments and challenges
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Emerging therapeutic agents for advanced non-small cell lung cancer
por: Chen, Ruqin, et al.
Publicado: (2020)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022)

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
por: Soyano, Aixa E., et al.
Publicado: (2018)

CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021)

Role of bridging therapy during chimeric antigen receptor T cell therapy
por: Bhaskar, Shakthi T., et al.
Publicado: (2021)

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers
por: Lou, Yanyan, et al.
Publicado: (2018)

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration
por: Gatwood, Katie S., et al.
Publicado: (2021)

Emerging therapeutic agents for genitourinary cancers
por: Zarrabi, Kevin, et al.
Publicado: (2019)

Emerging Therapeutic Agents for Colorectal Cancer
por: Nalli, Marianna, et al.
Publicado: (2021)

Securing the graft during pandemic: are we ready for cryopreservation for all?
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
por: Geethakumari, Praveen Ramakrishnan, et al.
Publicado: (2021)

Chimeric antigen receptor‐T cell therapies: The changing landscape
por: Sengsayadeth, Salyka M., et al.
Publicado: (2021)

Current therapy and development of therapeutic agents for lung cancer
por: Wang, Zilai, et al.
Publicado: (2022)

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
por: Li, Shenduo, et al.
Publicado: (2023)

Emerging Roles of microRNAs in Ischemic Stroke: As Possible Therapeutic Agents
por: Khoshnam, Seyed Esmaeil, et al.
Publicado: (2017)

New and emerging therapeutic agents for the treatment of fibromyalgia: an update
por: Recla, Jill M
Publicado: (2010)

Extracellular vesicles: Emerging tools as therapeutic agent carriers
por: Liu, Shan, et al.
Publicado: (2022)

Emergence of taurine as a therapeutic agent for neurological disorders
por: Jangra, Ashok, et al.
Publicado: (2023)

Antimicrobial de-escalation in patients with high-risk febrile neutropenia: Attitudes and practices of adult hospital care providers
por: Gorsline, Chelsea A., et al.
Publicado: (2021)

ADAM17: An Emerging Therapeutic Target for Lung Cancer
por: Saad, Mohamed I., et al.
Publicado: (2019)

The Ubiquitin System: An Emerging Therapeutic Target for Lung Cancer
por: Jin, Jun-O, et al.
Publicado: (2021)

Novel compounds in the treatment of lung cancer: current and developing therapeutic agents
por: Bao, Rudi, et al.
Publicado: (2011)

Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis
por: Hosten, Terron Anthony, et al.
Publicado: (2014)

Postbiotics as potential new therapeutic agents for sepsis
por: Lou, Xiran, et al.
Publicado: (2023)

Hesperidin: A Therapeutic Agent For Obesity
por: Xiong, Haijun, et al.
Publicado: (2019)

Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents
por: Wilton, Steve D, et al.
Publicado: (2011)

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
por: Zhang, Yiyin, et al.
Publicado: (2018)

Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
por: Athar, Teeba, et al.
Publicado: (2021)

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Epigenetic Modulators as Therapeutic Agents in Cancer
por: Patnaik, Eshaan, et al.
Publicado: (2023)

Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?
por: Reyes, Amanda, et al.
Publicado: (2023)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

Emerging Lung Cancer Therapeutic Targets Based on the Pathogenesis of Bone Metastases
por: Oyewumi, Moses O., et al.
Publicado: (2014)

Mitochondria targeting nano agents in cancer therapeutics
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Statin as a therapeutic agent in gastroenterological cancer
por: Uemura, Norio, et al.
Publicado: (2022)

Phytochemicals in Prostate Cancer: From Bioactive Molecules to Upcoming Therapeutic Agents
por: Salehi, Bahare, et al.
Publicado: (2019)

Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment
por: Lewis, Anne M, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_m8v4qk9eea5lt48fek5d36egg5